Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amneal PharmaceuticalsAMRX -1.49%54 3-Year EBITDA Growth Rate is 23.10% as of Jun. 2026. GuruFocus rates AMRX with a GF Score™ of 54/100 and a GF Value™ of $8.02 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 809 Drug Manufacturers companies, Amneal Pharmaceuticals ranks better than 72.81% on this metric.
During the past 12 months, Amneal Pharmaceuticals's average EBITDA Per Share Growth Rate was 3.30% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 23.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -5.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Amneal Pharmaceuticals was 62.60% per year. The lowest was -23.60% per year. And the median was -2.60% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Amneal Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms
AMRX vs HIMS, KNSA, INDV: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Amneal Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amneal Pharmaceuticals 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amneal Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Amneal Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 23.10% mean?
Amneal Pharmaceuticals (AMRX) has a 3-Year EBITDA Growth Rate of 23.10% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Amneal Pharmaceuticals and its competitors. According to the industry distribution chart, Amneal Pharmaceuticals ranks #220 out of 809 companies in the Drug Manufacturers industry, placing it in the top 27.2%.
Is Amneal Pharmaceuticals' 3-Year EBITDA Growth Rate too high?
Amneal Pharmaceuticals' current 3-Year EBITDA Growth Rate is 23.10%. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Amneal Pharmaceuticals' value of 23.10% is 159.6% above this industry median. Based on the distribution chart, Amneal Pharmaceuticals ranks #220 out of 809 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Amneal Pharmaceuticals has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amneal Pharmaceuticals' 3-Year EBITDA Growth Rate compare to HIMS and KNSA?
According to the Drug Manufacturers industry distribution chart, Amneal Pharmaceuticals ranks #220 out of 809 companies for 3-Year EBITDA Growth Rate. This puts Amneal Pharmaceuticals in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. Amneal Pharmaceuticals' value of 23.10% is 159.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amneal Pharmaceuticals's current 3-Year EBITDA Growth Rate of 23.10% is 159.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Amneal Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amneal Pharmaceuticals's current 3-Year EBITDA Growth Rate is 23.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amneal Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amneal Pharmaceuticals (AMRX) is currently considered Significantly Overvalued. The stock's GF Value™ is $8.02, compared to a current price of $17.88 — trading 122.9% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 23.10% and 159.6% above the Drug Manufacturers industry median of 8.90. Amneal Pharmaceuticals' overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Amneal Pharmaceuticals (AMRX), the current 3-Year EBITDA Growth Rate is 23.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amneal Pharmaceuticals (AMRX) Overvalued in 2026?
Based on GuruFocus' analysis, Amneal Pharmaceuticals stock appears to be overvalued.
The current stock price of $17.88 is trading 122.9% above its estimated GF Value™ of $8.02.
GuruFocus considers Amneal Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for AMRX:
3-Year EBITDA Growth Rate: 23.10%
GF Value™: $8.02 vs. price of $17.88 (122.9% above fair value)
Industry Position: 159.6% above the Drug Manufacturers median (#220 of 809)
No single metric tells the full story. See the AMRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
54GF Score
Get the complete analysis for AMRX
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMRX has been successfully added to your 
